Ruplizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD154 |
| Clinical data | |
| Trade names | Antova |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms,[1] while another study only found thrombocytopenia.[2]
References
[edit]- ^ Liossis SN, Sfikakis PP (2004). "Costimulation blockade in the treatment of rheumatic diseases". BioDrugs. 18 (2): 95–102. doi:10.2165/00063030-200418020-00003. PMID 15046525. S2CID 24762590.
- ^ Nakamura M, Tanaka Y, Satoh T, Kawai M, Hirakata M, Kaburaki J, et al. (February 2006). "Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism". Rheumatology. 45 (2): 150–6. doi:10.1093/rheumatology/kei118. PMID 16188945.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |